Literature DB >> 16923919

HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.

Maureen M Goodenow1, Ronald G Collman.   

Abstract

HIV-1 infection of cells is mediated by engagement between viral envelope glycoproteins (Env) and a receptor complex comprising CD4 and one of two chemokine receptors, CCR5 and CXCR4, expressed on the surface of target cells. Most CD4+-transformed T cell lines express only CXCR4, but primary lymphocytes and macrophages, the main cellular targets for infection in vivo, express both coreceptors. Cell- and viral strain-specific utilization of these coreceptor pathways, rather than coreceptor expression per se, regulates lymphocyte and macrophage entry and tropism. Virus use of coreceptor[s] (R5, X4, or R5 and X4) and its target cell tropism (lymphocytes, macrophages, and/or transformed T cell lines) are related but distinct characteristics of Envs. A comprehensive classification schema of HIV-1 Env phenotypes that addresses both tropism and coreceptor use is proposed. Defining Env phenotype based on both parameters is important in the development of entry inhibitors and vaccines, for understanding changes in Env that evolve over time in vivo, and for discerning differences among viral species that underlie aspects of pathogenesis and transmission. Recognizing how tropism is related to, yet differs from, coreceptor selectivity is critical for understanding the mechanisms by which these viral characteristics impact pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923919     DOI: 10.1189/jlb.0306148

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  45 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region.

Authors:  Menghua Zhang; Stella Evans; Jinyun Yuan; Lee Ratner; Prasad S Koka
Journal:  Virology       Date:  2010-03-24       Impact factor: 3.616

5.  Preventing and exploiting the oncogenic potential of integrating gene vectors.

Authors:  Ute Modlich; Christopher Baum
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

6.  Prediction of R5, X4, and R5X4 HIV-1 coreceptor usage with evolved neural networks.

Authors:  Susanna L Lamers; Marco Salemi; Michael S McGrath; Gary B Fogel
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2008 Apr-Jun       Impact factor: 3.710

7.  Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B.

Authors:  Laura Monno; Annalisa Saracino; Luigia Scudeller; Grazia Punzi; Gaetano Brindicci; Maurantonio Altamura; Antonella Lagioia; Nicoletta Ladisa; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

8.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.

Authors:  Kathryn H Richards; Marlén Mi Aasa-Chapman; Aine McKnight; Paul R Clapham
Journal:  Retrovirology       Date:  2010-05-27       Impact factor: 4.602

10.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.